The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 18, 2017
Filed:
Mar. 25, 2014
Consejo Nacional DE Investigaciones Cientificas Y Tecnicas (Conicet), Buenos Aires, AR;
Universidad Nacional DE LA Plata, La-Plata-Buenos Aires, AR;
Inis Biotech Llc, Milford, Kent County, DE (US);
Daniela Hozbor, Buenos Aires, AR;
Daniela Bottero, La Plata-Buenos Aires, AR;
María Emilia Gaillard, La Plata-Buenos Aires, AR;
Eugenia Zurita, La Plata-Buenos Aires, AR;
Maximiliano Omazabal, Bell-Buenos Aires, AR;
Darío Flores, La Plata-Buenos Aires, AR;
Agustina Errea, La Plata-Buenos Aires, AR;
Griselda Moreno, La Plata-Buenos Aires, AR;
Martin Rumbo, Bell-Buenos Aires, AR;
Erika Bartel, La Plata-Buenos Aires, AR;
Celina Castuma, La Plata-Buenos Aires, AR;
CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECHNICAS (CONICET), Buenos Aires, AR;
UNIVERSIDAD NACIONAL DE LA PLATA, Buenos Aires, AR;
INIS BIOTECH LLC, Milford, DE (US);
Abstract
A vaccine for the prevention of infections with, comprising at least outer membrane vesicles (OMVs) of, excipients and/or adjuvants.may be, for example,or. The vaccine can comprise adjuvants, for example, aluminum hydroxide and other immunogens such as tetanus toxoid, diphtheria toxoid, or combinations thereof. In another preferred embodiment, the vaccine for the prevention of infections withcomprises at least outer membrane vesicles (OMVs) ofand the lipopolysaccharide of, excipients and/or adjuvants. The vaccine can comprise between 3 to 20 μg per dose of OMVs fromand between the amount equivalent to 10and 10bacteria per dose of lipopolysaccharide of. The adjuvant can be aluminum hydroxide and other immunogens such as tetanus toxoid, diphtheria toxoid, or combinations thereof. The Tdap vaccine exhibits cross activity.